Project Grant R01HL175339
Award Date
5/1/25
Completion Date
2/28/29
Dollars Obligated
$596K
Federal Agency
National Heart Lung and Blood Institute
Federal Grant Program
93.837
Assistance Type
Project Grant
Place of Performance
Indiana, USA
Similar Awards
This $717,415 Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), supports research to investigate the role of the TET2-mediated RNA 5-methylcytosine (m5C) modification axis in regulating hematopoietic stem/progenitor cell (HSPC) function. The primary research objectives are to: Define the importance of TET2-mediated chromatin-associated RNA (CARNA) m5C oxidation in HSPC regulation, including...
The National Heart, Lung, and Blood Institute (NHLBI) awarded a $711,039 Project Grant (CFDA 93.837 - Cardiovascular Diseases Research) to the Research Institute at Nationwide Children's Hospital (RINCH) to investigate the role of cardiac m6A methyltransferases in the pathogenesis of early-onset dilated cardiomyopathy (DCM) in fetuses. The project aims to determine the functions of the m6A methyltransferase subunits METTL3 and METTL14 in embryonic mouse myocardium, and whether their...
This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), provides $792,498 in funding to the Trustees of Indiana University, doing business as Indiana University Indianapolis, to conduct research on the regulation of hematopoietic stem cells under low oxygen tension. The key objectives of this 4-year project are to: 1) determine how hypoxia activates the transcription factor TFE3 to facilitate...
The National Heart, Lung, and Blood Institute (NHLBI) awarded a $749,769 Project Grant (R01HL171205) under the Cardiovascular Diseases Research program (CFDA 93.837) to The Johns Hopkins University. The project aims to investigate the dysregulated maturation of pluripotent stem cell-derived cardiomyocytes (PSC-CMs) and develop a transcriptome-based approach to improve their clinical viability. Specifically, the research will identify the critical gene regulatory network underlying the...
The federal Project Grant award under the Cardiovascular Diseases Research program (CFDA 93.837) from the National Heart, Lung, and Blood Institute (NHLBI) will provide $243,000.00 from January 1, 2025 to December 31, 2026 to the University of Cincinnati. This exploratory study aims to address challenges related to the efficiency and specificity of converting fibroblasts (connective tissue cells) into cardiac cells for in vivo heart regeneration. The research will focus on innovatively...
This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) provides $487,567 to Indiana University to conduct integrative genomic analysis and develop high-dimensional risk prediction models for congenital heart defects (CHDs). The research aims to identify genetic variants and biological pathways associated with CHDs, as well as build predictive models leveraging genetic, epigenetic,...
This $657,368 federal project grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) will support research to investigate the regulation of microRNA (miRNA) processing and degradation pathways during hematopoietic development. The primary awardee, The Washington University, will use human pluripotent stem cell lines with mutations in miRNA regulatory genes to derive hematopoietic cells in vitro and study the...
This federal Project Grant award of $2,251,975.00, funded by the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), aims to identify unrecognized genetic causes of congenital heart disease (CHD). The award supports research with the following key objectives: Assessing the contribution of de novo non-coding variants of unknown significance (NCDNV) to unexplained CHD cases. Defining the contribution of rare coding region variants...
This Project Grant award of $751,747 from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research federal grant program (CFDA 93.837), supports research on the transcriptional and post-transcriptional regulation of cardiomyocyte (CM) maturation. The research program at the University of North Carolina at Chapel Hill aims to define the critical role of the CARM1 protein in controlling multiple aspects of CM structural, functional, and electrophysiological...
This $2,275,731.00 Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), part of the Cardiovascular Diseases Research program (CFDA 93.837), supports research to characterize multilineage definitive hematopoietic (blood) progenitor cells derived from human pluripotent stem cells. The overarching goal is to understand how to efficiently generate hematopoietic stem cells, an important source for cell therapies and disease modeling, from human pluripotent stem cells in...